Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous blinatumomab-expanded T cells

A preparation of autologous, peripheral blood-derived polyclonal activated T cells that have been expanded and activated ex-vivo using blinatumomab and recombinant human IL2 (rhIL-2) and depleted of contaminating CD19+ tumor cells, with potential immunomodulating activity. Upon administration, these blinatumomab-expanded T cells (BET), composed of functional polyclonal CD4+ and CD8+ T cells and mostly effector and central memory cells, may induce immunological recovery. BET cell expansion leads to the lysis and elimination of contaminating CD19+ tumor cells. The elimination of contaminating tumor cells is important in the treatment of non-Hodgkin CD20 + indolent lymphoma (iNHL) and chronic lymphatic leukemia (CLL).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:BET
blinatumomab-cultured T cells
blinatumomab-expanded peripheral blood-derived T cells
blinatumomab-expanded T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search